Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis

Rachel G. Greenberg, Daniel K. Benjamin, Marie G. Gantz, C. Michael Cotten, Barbara J. Stoll, Michele C. Walsh, Pablo J. Sánchez, Seetha Shankaran, Abhik Das, Rosemary D. Higgins, Nancy A. Miller, Kathy J. Auten, Thomas J. Walsh, Abbot R. Laptook, Waldemar A. Carlo, Kathleen A. Kennedy, Neil N. Finer, Shahnaz Duara, Kurt Schibler, Richard A. EhrenkranzKrisa P. Van Meurs, Ivan D. Frantz, Dale L. Phelps, Brenda B. Poindexter, Edward F. Bell, T. Michael O'Shea, Kristi L. Watterberg, Ronald N. Goldberg, P. Brian Smith

Research output: Contribution to journalArticle

Abstract

Objective: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. Study design: This was a cohort study of infants with a birth weight ≤1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). Results: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. Conclusion: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.

Original languageEnglish (US)
JournalJournal of Pediatrics
Volume161
Issue number2
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Invasive Candidiasis
Extremely Low Birth Weight Infant
Candida
Logistic Models
Therapeutics
Bronchopulmonary Dysplasia
Propensity Score
Retinopathy of Prematurity
Birth Weight
Premature Infants
Cohort Studies
Incidence
Infection
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Greenberg, R. G., Benjamin, D. K., Gantz, M. G., Cotten, C. M., Stoll, B. J., Walsh, M. C., ... Smith, P. B. (2012). Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. Journal of Pediatrics, 161(2). https://doi.org/10.1016/j.jpeds.2012.01.053

Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. / Greenberg, Rachel G.; Benjamin, Daniel K.; Gantz, Marie G.; Cotten, C. Michael; Stoll, Barbara J.; Walsh, Michele C.; Sánchez, Pablo J.; Shankaran, Seetha; Das, Abhik; Higgins, Rosemary D.; Miller, Nancy A.; Auten, Kathy J.; Walsh, Thomas J.; Laptook, Abbot R.; Carlo, Waldemar A.; Kennedy, Kathleen A.; Finer, Neil N.; Duara, Shahnaz; Schibler, Kurt; Ehrenkranz, Richard A.; Van Meurs, Krisa P.; Frantz, Ivan D.; Phelps, Dale L.; Poindexter, Brenda B.; Bell, Edward F.; O'Shea, T. Michael; Watterberg, Kristi L.; Goldberg, Ronald N.; Smith, P. Brian.

In: Journal of Pediatrics, Vol. 161, No. 2, 08.2012.

Research output: Contribution to journalArticle

Greenberg, RG, Benjamin, DK, Gantz, MG, Cotten, CM, Stoll, BJ, Walsh, MC, Sánchez, PJ, Shankaran, S, Das, A, Higgins, RD, Miller, NA, Auten, KJ, Walsh, TJ, Laptook, AR, Carlo, WA, Kennedy, KA, Finer, NN, Duara, S, Schibler, K, Ehrenkranz, RA, Van Meurs, KP, Frantz, ID, Phelps, DL, Poindexter, BB, Bell, EF, O'Shea, TM, Watterberg, KL, Goldberg, RN & Smith, PB 2012, 'Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis', Journal of Pediatrics, vol. 161, no. 2. https://doi.org/10.1016/j.jpeds.2012.01.053
Greenberg, Rachel G. ; Benjamin, Daniel K. ; Gantz, Marie G. ; Cotten, C. Michael ; Stoll, Barbara J. ; Walsh, Michele C. ; Sánchez, Pablo J. ; Shankaran, Seetha ; Das, Abhik ; Higgins, Rosemary D. ; Miller, Nancy A. ; Auten, Kathy J. ; Walsh, Thomas J. ; Laptook, Abbot R. ; Carlo, Waldemar A. ; Kennedy, Kathleen A. ; Finer, Neil N. ; Duara, Shahnaz ; Schibler, Kurt ; Ehrenkranz, Richard A. ; Van Meurs, Krisa P. ; Frantz, Ivan D. ; Phelps, Dale L. ; Poindexter, Brenda B. ; Bell, Edward F. ; O'Shea, T. Michael ; Watterberg, Kristi L. ; Goldberg, Ronald N. ; Smith, P. Brian. / Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. In: Journal of Pediatrics. 2012 ; Vol. 161, No. 2.
@article{5886aaf896c6412db15cf62266ba7ea7,
title = "Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis",
abstract = "Objective: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. Study design: This was a cohort study of infants with a birth weight ≤1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). Results: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50{\%}) compared with those who had not (55 of 86; 64{\%}; OR, 0.27; 95{\%} CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. Conclusion: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.",
author = "Greenberg, {Rachel G.} and Benjamin, {Daniel K.} and Gantz, {Marie G.} and Cotten, {C. Michael} and Stoll, {Barbara J.} and Walsh, {Michele C.} and S{\'a}nchez, {Pablo J.} and Seetha Shankaran and Abhik Das and Higgins, {Rosemary D.} and Miller, {Nancy A.} and Auten, {Kathy J.} and Walsh, {Thomas J.} and Laptook, {Abbot R.} and Carlo, {Waldemar A.} and Kennedy, {Kathleen A.} and Finer, {Neil N.} and Shahnaz Duara and Kurt Schibler and Ehrenkranz, {Richard A.} and {Van Meurs}, {Krisa P.} and Frantz, {Ivan D.} and Phelps, {Dale L.} and Poindexter, {Brenda B.} and Bell, {Edward F.} and O'Shea, {T. Michael} and Watterberg, {Kristi L.} and Goldberg, {Ronald N.} and Smith, {P. Brian}",
year = "2012",
month = "8",
doi = "10.1016/j.jpeds.2012.01.053",
language = "English (US)",
volume = "161",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis

AU - Greenberg, Rachel G.

AU - Benjamin, Daniel K.

AU - Gantz, Marie G.

AU - Cotten, C. Michael

AU - Stoll, Barbara J.

AU - Walsh, Michele C.

AU - Sánchez, Pablo J.

AU - Shankaran, Seetha

AU - Das, Abhik

AU - Higgins, Rosemary D.

AU - Miller, Nancy A.

AU - Auten, Kathy J.

AU - Walsh, Thomas J.

AU - Laptook, Abbot R.

AU - Carlo, Waldemar A.

AU - Kennedy, Kathleen A.

AU - Finer, Neil N.

AU - Duara, Shahnaz

AU - Schibler, Kurt

AU - Ehrenkranz, Richard A.

AU - Van Meurs, Krisa P.

AU - Frantz, Ivan D.

AU - Phelps, Dale L.

AU - Poindexter, Brenda B.

AU - Bell, Edward F.

AU - O'Shea, T. Michael

AU - Watterberg, Kristi L.

AU - Goldberg, Ronald N.

AU - Smith, P. Brian

PY - 2012/8

Y1 - 2012/8

N2 - Objective: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. Study design: This was a cohort study of infants with a birth weight ≤1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). Results: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. Conclusion: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.

AB - Objective: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. Study design: This was a cohort study of infants with a birth weight ≤1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). Results: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. Conclusion: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84864287628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864287628&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2012.01.053

DO - 10.1016/j.jpeds.2012.01.053

M3 - Article

C2 - 22424952

AN - SCOPUS:84864287628

VL - 161

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -